CD24 and hepatocellular carcinoma: By connecting a CD24-targeting antibody (G7mAb) to two doxorubicin molecules [29] or monomethyl auristatin E [30], the resulting ADCs were able to suppress tumor growth, decrease systemic toxicity, and prolong the survival of HCC-bearing nude mice.